Ítem
Acceso Abierto

Factores Genéticos y no genéticos asociados a la severidad clínica de la infección por SARS-CoV-2 y COVID-19 prolongado en una muestra de la población colombiana

Mostrar el registro sencillo de la publicación
dc.contributor.advisorFonseca Mendoza, Dora Janeth
dc.contributor.advisorOrtega Relcalde, Oscar Javier
dc.contributor.advisorOspina, María Cristina
dc.creatorAngulo Aguado, Mariana
dc.creatorCarrillo Martínez, Juan Camilo
dc.creator.degreeMagíster en Epidemiología
dc.creator.degreeLevelMaestría
dc.creator.degreetypeFull time
dc.date.accessioned2023-07-06T17:46:02Z
dc.date.available2023-07-06T17:46:02Z
dc.date.created2023-06-20
dc.date.embargoEndinfo:eu-repo/date/embargoEnd/2023-09-07
dc.descriptionIntroducción: Existe una heterogenea respuesta a la infección por SARS-CoV-2 dada por variabilidad interindividual mediada por factores clínicos, virales y genéticos del huésped. Pocos estudios a nivel latinoamericano han explorado la implicación de variantes genéticas en la variabilidad fenotípica de la evolución y desenlaces de esta enfermedad. El principal objetivo del estudio fue evaluar la asociación de factores clínicos y genéticos con la severidad de COVID-19 y la presencia de COVID-19 prolongado. Metodología: Utilizando un diseño metodológico tipo casos y controles (n = 112; 1:1). Se recolectaron variables clínicas, sociodemográficas, y genéticas a través de encuestas, la historia clínica y secuenciación de siguiente generación (NGS). Se determinó la asociación de las variables clínicas y de 81 polimorfismos de nucleótido simple (SNP) con severidad de COVID-19 y presencia de COVID-19 prolongado. Las variables significativas se usaron para construir un modelo predictivo de severidad de COVID-19 y COVID-19 prolongado. Resultados y discusión: En concordancia con reportes previos, variables clínicas como sexo masculino, obesidad, diabetes mellitus, tos, disnea, entre otras, exhibieron asociación estadísticamente significativa con la severidad a COVID-19. Varios SNP presentaron asociación significativa con severidad, tales como rs11385942 (p<0.01; OR=10.88; 95% CI=1.36-86.51), rs10490770 (p<0.01; OR=9.699; 95% CI=1.20-77.89), rs35081325 (p<0.01; OR=9.699; 95% CI=1.20-77.89) y rs73064425 (p<0.01; OR=9.699; 95% CI=1.20-77.89). Múltiples síntomas respiratorios y sistémicos presentes durante la infección tuvieron asociación con la presencia de COVID-19 prolongado, al igual que algunos SNP como rs8178521 del gen IL10RB (p<0.01; OR=2.51; 95% CI=1.27-4.94). Se ilustró que los modelos mixtos que integran variables clínicas y genéticas tienen el mejor poder predictivo.
dc.description.abstractIntroduction: There is a heterogeneous response to SARS-CoV-2 infection given by interindividual variability mediated by clinical, viral and genetic factors of the host. Few studies at the Latin American level have explored the involvement of genetic variants in the phenotypic variability of the evolution and outcomes of this disease. The main objective of the study was to evaluate the association of clinical and genetic factors with the severity of COVID-19 and the presence of prolonged COVID-19. Methodology: Using a case-control methodological design (n = 112; 1:1). Clinical, sociodemographic, and genetic variables were collected through surveys, clinical history, and next-generation sequencing (NGS). The association of clinical variables and 81 single nucleotide polymorphisms (SNPs) with severity of COVID-19 and presence of prolonged COVID-19 was determined. Significant variables were used to build a predictive model of COVID-19 severity and prolonged COVID-19. Results and discussion: In accordance with previous reports, clinical variables such as male sex, obesity, diabetes mellitus, cough, dyspnea, among others, exhibited a statistically significant association with the severity of COVID-19. Several SNPs presented a significant association with severity, such as rs11385942 (p<0.01; OR=10.88; 95% CI=1.36-86.51), rs10490770 (p<0.01; OR=9.699; 95% CI=1.20-77.89), rs35081325 ( p<0.01; OR=9.699; 95% CI=1.20-77.89) and rs73064425 (p<0.01; OR=9.699; 95% CI=1.20-77.89). Multiple respiratory and systemic symptoms present during the infection were associated with the presence of prolonged COVID-19, as were some SNPs such as IL10RB gene rs8178521 (p<0.01; OR=2.51; 95% CI=1.27-4.94). It was illustrated that mixed models that integrate clinical and genetic variables have the best predictive power.
dc.description.sponsorshipUniversidad del Rosario
dc.description.sponsorshipHospital Universitario Mayor Méderi
dc.format.extent92 pp
dc.format.mimetypeapplication/pdf
dc.identifier.doihttps://doi.org/10.48713/10336_40065
dc.identifier.urihttps://repository.urosario.edu.co/handle/10336/40065
dc.language.isospa
dc.publisherUniversidad del Rosariospa
dc.publisher.departmentEscuela de Medicina y Ciencias de la Saludspa
dc.publisher.programMaestría en Epidemiologíaspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International*
dc.rights.accesRightsinfo:eu-repo/semantics/embargoedAccess
dc.rights.accesoRestringido (Temporalmente bloqueado)
dc.rights.economicrightsUniversidad del Rosario
dc.rights.licenciaEL AUTOR, manifiesta que la obra objeto de la presente autorización es original y la realizó sin violar o usurpar derechos de autor de terceros, por lo tanto la obra es de exclusiva autoría y tiene la titularidad sobre la misma. PARGRAFO: En caso de presentarse cualquier reclamación o acción por parte de un tercero en cuanto a los derechos de autor sobre la obra en cuestión, EL AUTOR, asumirá toda la responsabilidad, y saldrá en defensa de los derechos aquí autorizados; para todos los efectos la universidad actúa como un tercero de buena fe. EL AUTOR, autoriza a LA UNIVERSIDAD DEL ROSARIO, para que en los términos establecidos en la Ley 23 de 1982, Ley 44 de 1993, Decisión andina 351 de 1993, Decreto 460 de 1995 y demás normas generales sobre la materia, utilice y use la obra objeto de la presente autorización. -------------------------------------- POLITICA DE TRATAMIENTO DE DATOS PERSONALES. Declaro que autorizo previa y de forma informada el tratamiento de mis datos personales por parte de LA UNIVERSIDAD DEL ROSARIO para fines académicos y en aplicación de convenios con terceros o servicios conexos con actividades propias de la academia, con estricto cumplimiento de los principios de ley. Para el correcto ejercicio de mi derecho de habeas data cuento con la cuenta de correo habeasdata@urosario.edu.co, donde previa identificación podré solicitar la consulta, corrección y supresión de mis datos.spa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.source.bibliographicCitationOMS. Emergencies. 2022 [citado 19 de diciembre de 2022]. Coronavirus disease (COVID-19) pandemic. Disponible en: https://www.who.int/europe/emergencies/situations/covid-19
dc.source.bibliographicCitationCOVID - Coronavirus Statistics - Worldometer [Internet]. [citado 2 de mayo de 2023]. Disponible en: https://www.worldometers.info/coronavirus/
dc.source.bibliographicCitationJohn Hopkins University. CoVID19 dashboard. 2022 [citado 19 de diciembre de 2022]. Coronavirus world Map. Disponible en: https://gisanddata.maps.arcgis.com/apps/dashboards/bda7594740fd40299423467b48e9ecf6
dc.source.bibliographicCitationLefkowitz EJ, Dempsey DM, Hendrickson RC, Orton RJ, Siddell SG, Smith DB. Virus taxonomy: the database of the International Committee on Taxonomy of Viruses (ICTV). Nucleic Acids Res. 4 de enero de 2018;46(D1):D708-17.
dc.source.bibliographicCitationYuki K, Fujiogi M, Koutsogiannaki S. COVID-19 pathophysiology: A review. Clin Immunol. junio de 2020;215:108427.
dc.source.bibliographicCitationHu B, Guo H, Zhou P, Shi ZL. Characteristics of SARS-CoV-2 and COVID-19. Nat Rev Microbiol. marzo de 2021;19(3):141-54.
dc.source.bibliographicCitationAdil MT, Rahman R, Whitelaw D, Jain V, Al-Taan O, Rashid F, et al. SARS-CoV-2 and the pandemic of COVID-19. Postgrad Med J. febrero de 2021;97(1144):110-6.
dc.source.bibliographicCitationReport of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) [Internet]. 2022 [citado 19 de diciembre de 2022]. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). Disponible en: https://www.who.int/publications-detail-redirect/report-of-the-who-china-joint-mission-on-coronavirus-disease-2019-(covid-19)
dc.source.bibliographicCitationCarfì A, Bernabei R, Landi F, for the Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 11 de agosto de 2020;324(6):603.
dc.source.bibliographicCitationLogue JK, Franko NM, McCulloch DJ, McDonald D, Magedson A, Wolf CR, et al. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw Open. 19 de febrero de 2021;4(2):e210830.
dc.source.bibliographicCitationOvsyannikova IG, Haralambieva IH, Crooke SN, Poland GA, Kennedy RB. The role of host genetics in the immune response to SARS‐CoV‐2 and COVID‐19 susceptibility and severity. Immunol Rev. julio de 2020;296(1):205-19.
dc.source.bibliographicCitationClouston SAP, Luft BJ, Sun E. Clinical risk factors for mortality in an analysis of 1375 patients admitted for COVID treatment. Sci Rep. 3 de diciembre de 2021;11(1):23414.
dc.source.bibliographicCitationForster P, Forster L, Renfrew C, Forster M. Phylogenetic network analysis of SARS-CoV-2 genomes. Proc Natl Acad Sci. 28 de abril de 2020;117(17):9241-3
dc.source.bibliographicCitationVelavan TP, Pallerla SR, Rüter J, Augustin Y, Kremsner PG, Krishna S, et al. Host genetic factors determining COVID-19 susceptibility and severity. eBioMedicine. octubre de 2021;72:103629
dc.source.bibliographicCitationThe GenOMICC Investigators, The ISARIC4C Investigators, The COVID-19 Human Genetics Initiative, 23andMe Investigators, BRACOVID Investigators, Gen-COVID Investigators, et al. Genetic mechanisms of critical illness in COVID-19. Nature. 4 de marzo de 2021;591(7848):92-8.
dc.source.bibliographicCitationWang F, Huang S, Gao R, Zhou Y, Lai C, Li Z, et al. Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov. 10 de noviembre de 2020;6(1):83.
dc.source.bibliographicCitationMousa M, Vurivi H, Kannout H, Uddin M, Alkaabi N, Mahboub B, et al. Genome-wide association study of hospitalized COVID-19 patients in the United Arab Emirates. eBioMedicine. diciembre de 2021;74:103695.
dc.source.bibliographicCitationThe Severe Covid-19 GWAS Group. Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med. 15 de octubre de 2020;383(16):1522-34.
dc.source.bibliographicCitationCOVID-19 Host Genetics Initiative, COVID-19 Host Genetics InitiativeLeadership, Niemi MEK, Karjalainen J, Liao RG, Neale BM, et al. Mapping the human genetic architecture of COVID-19. Nature. 16 de diciembre de 2021;600(7889):472-7.
dc.source.bibliographicCitationProal AD, VanElzakker MB. Long COVID or Post-acute Sequelae of COVID-19 (PASC): An Overview of Biological Factors That May Contribute to Persistent Symptoms. Front Microbiol. 23 de junio de 2021;12:698169.
dc.source.bibliographicCitationWeekly epidemiological update on COVID-19 [Internet]. 2022 [citado 19 de diciembre de 2022]. Weekly epidemiological update on COVID-19 - 30 November 2022. Disponible en: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---30-november-2022
dc.source.bibliographicCitationReportes de Situación COVID-19: Colombia [Internet]. 2022 [citado 19 de diciembre de 2022]. Reportes de Situación COVID-19: Colombia | OPS/OMS | Organización Panamericana de la Salud. Disponible en: https://www.paho.org/es/reportes-situacion-covid-19-colombia
dc.source.bibliographicCitationCOVID19 en Colombia [Internet]. 2022 [citado 19 de diciembre de 2022]. Noticias coronavirus-casos. Disponible en: https://www.ins.gov.co/Noticias/Paginas/coronavirus-casos.aspx
dc.source.bibliographicCitationBooth A, Reed AB, Ponzo S, Yassaee A, Aral M, Plans D, et al. Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. Madeddu G, editor. PLOS ONE. 4 de marzo de 2021;16(3):e0247461.
dc.source.bibliographicCitationYildirim Z, Sahin OS, Yazar S, Bozok Cetintas V. Genetic and epigenetic factors associated with increased severity of Covid‐19. Cell Biol Int. junio de 2021;45(6):1158-74.
dc.source.bibliographicCitationSuh S, Lee S, Gym H, Yoon S, Park S, Cha J, et al. A systematic review on papers that study on Single Nucleotide Polymorphism that affects coronavirus 2019 severity. BMC Infect Dis. diciembre de 2022;22(1):47.
dc.source.bibliographicCitationCOVID19 hg [Internet]. 2022 [citado 20 de diciembre de 2022]. COVID-19 Host Genetics Initiative. Disponible en: https://www.covid19hg.org/partners/
dc.source.bibliographicCitationSecolin R, de Araujo TK, Gonsales MC, Rocha CS, Naslavsky M, Marco LD, et al. Genetic variability in COVID-19-related genes in the Brazilian population. Hum Genome Var. 2 de abril de 2021;8(1):15.
dc.source.bibliographicCitationite GS, Murphy NM, Allman R. An integrated clinical and genetic model for predicting risk of severe COVID-19: A population-based case–control study. Novelli G, editor. PLOS ONE. 16 de febrero de 2021;16(2):e0247205.
dc.source.bibliographicCitationZhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 12 de marzo de 2020;579(7798):270-3.
dc.source.bibliographicCitationCui J, Li F, Shi ZL. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. marzo de 2019;17(3):181-92
dc.source.bibliographicCitationXiao K, Zhai J, Feng Y, Zhou N, Zhang X, Zou JJ, et al. Isolation of SARS-CoV-2-related coronavirus from Malayan pangolins. Nature. 9 de julio de 2020;583(7815):286-9.
dc.source.bibliographicCitationShi Y, Wang G, Cai X peng, Deng J wen, Zheng L, Zhu H hong, et al. An overview of COVID-19. J Zhejiang Univ-Sci B. mayo de 2020;21(5):343-60.
dc.source.bibliographicCitationCastañeda S, Patiño LH, Muñoz M, Ballesteros N, Guerrero-Araya E, Paredes-Sabja D, et al. Evolution and Epidemic Spread of SARS-CoV-2 in Colombia: A Year into the Pandemic. Vaccines. 30 de julio de 2021;9(8):837
dc.source.bibliographicCitationJimenez-Silva C, Rivero R, Douglas J, Bouckaert R, Villabona-Arenas J, Atkins K, et al. Genomic epidemiology of circulating SARS-CoV-2 variants during first two years of the pandemic in Colombia [Internet]. Genetic and Genomic Medicine; 2022 jun [citado 4 de julio de 2023]. Disponible en: http://medrxiv.org/lookup/doi/10.1101/2022.06.20.22275744
dc.source.bibliographicCitationVarela AR, Florez LJH, Tamayo-Cabeza G, Contreras-Arrieta S, Restrepo SR, Laajaj R, et al. Factors Associated With SARS-CoV-2 Infection in Bogotá, Colombia: Results From a Large Epidemiological Surveillance Study. Lancet Reg Health - Am. octubre de 2021;2:100048
dc.source.bibliographicCitationCDC. Centers for Disease Control and Prevention. 2020 [citado 20 de diciembre de 2022]. COVID-19 and Your Health. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/your-health/understanding-risk.html
dc.source.bibliographicCitationAngulo-Aguado M, Corredor-Orlandelli D, Carrillo-Martínez JC, Gonzalez-Cornejo M, Pineda-Mateus E, Rojas C, et al. Association Between the LZTFL1 rs11385942 Polymorphism and COVID-19 Severity in Colombian Population. Front Med. 20 de junio de 2022;9:910098.
dc.source.bibliographicCitationLi MY, Li L, Zhang Y, Wang XS. Expression of the SARS-CoV-2 cell receptor gene ACE2 in a wide variety of human tissues. Infect Dis Poverty. diciembre de 2020;9(1):45.
dc.source.bibliographicCitationSingh SP, Pritam M, Pandey B, Yadav TP. Microstructure, pathophysiology, and potential therapeutics of COVID‐19: A comprehensive review. J Med Virol. enero de 2021;93(1):275-99.
dc.source.bibliographicCitationMarik PE, Iglesias J, Varon J, Kory P. A scoping review of the pathophysiology of COVID-19. Int J Immunopathol Pharmacol. enero de 2021;35:205873842110480.
dc.source.bibliographicCitationBlanco-Melo D, Nilsson-Payant BE, Liu WC, Uhl S, Hoagland D, Møller R, et al. Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19. Cell. mayo de 2020;181(5):1036-1045.e9
dc.source.bibliographicCitationFarag NS, Breitinger U, Breitinger HG, El Azizi MA. Viroporins and inflammasomes: A key to understand virus-induced inflammation. Int J Biochem Cell Biol. mayo de 2020;122:105738.
dc.source.bibliographicCitationVan Damme W, Dahake R, van de Pas R, Vanham G, Assefa Y. COVID-19: Does the infectious inoculum dose-response relationship contribute to understanding heterogeneity in disease severity and transmission dynamics? Med Hypotheses. enero de 2021;146:110431
dc.source.bibliographicCitationHou YJ, Okuda K, Edwards CE, Martinez DR, Asakura T, Dinnon KH, et al. SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract. Cell. julio de 2020;182(2):429-446.e14.
dc.source.bibliographicCitationLeisman DE, Deutschman CS, Legrand M. Facing COVID-19 in the ICU: vascular dysfunction, thrombosis, and dysregulated inflammation. Intensive Care Med. junio de 2020;46(6):1105-8.
dc.source.bibliographicCitationGustine JN, Jones D. Immunopathology of Hyperinflammation in COVID-19. Am J Pathol. enero de 2021;191(1):4-17.
dc.source.bibliographicCitationGuan W jie, Ni Z yi, Hu Y, Liang W hua, Ou C quan, He J xing, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 30 de abril de 2020;382(18):1708-20.
dc.source.bibliographicCitationWu Y, Kang L, Guo Z, Liu J, Liu M, Liang W. Incubation Period of COVID-19 Caused by Unique SARS-CoV-2 Strains: A Systematic Review and Meta-analysis. JAMA Netw Open. 22 de agosto de 2022;5(8):e2228008.
dc.source.bibliographicCitationCDC. Centers for Disease Control and Prevention. 2020 [citado 20 de diciembre de 2022]. Healthcare Workers. Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/clinical-considerations-course.html
dc.source.bibliographicCitationStokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, El Burai Felix S, et al. Coronavirus Disease 2019 Case Surveillance — United States, January 22–May 30, 2020. MMWR Morb Mortal Wkly Rep. 19 de junio de 2020;69(24):759-65.
dc.source.bibliographicCitationWhitaker M, Elliott J, Bodinier B, Barclay W, Ward H, Cooke G, et al. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. Nat Commun. 11 de noviembre de 2022;13(1):6856.
dc.source.bibliographicCitationMa Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. JAMA Netw Open. 14 de diciembre de 2021;4(12):e2137257.
dc.source.bibliographicCitationWu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. 7 de abril de 2020;323(13):1239.
dc.source.bibliographicCitationSaavedra Trujillo CH. Consenso colombiano de atención, diagnóstico y manejo de la infección por SARS-COV-2/COVID 19 en establecimientos de atención de la salud. Recomendaciones basadas en consenso de expertos e informadas en la evidencia. Infectio. 26 de marzo de 2020;24(3):1.
dc.source.bibliographicCitationCoronavirus disease (COVID-19): Post COVID-19 condition [Internet]. 2022 [citado 20 de diciembre de 2022]. Coronavirus disease (COVID-19): Post COVID-19 condition. Disponible en: https://www.who.int/news-room/questions-and-answers/item/coronavirus-disease-(covid-19)-post-covid-19-condition
dc.source.bibliographicCitationNasserie T, Hittle M, Goodman SN. Assessment of the Frequency and Variety of Persistent Symptoms Among Patients With COVID-19: A Systematic Review. JAMA Netw Open. 26 de mayo de 2021;4(5):e2111417.
dc.source.bibliographicCitationCarvalho-Schneider C, Laurent E, Lemaignen A, Beaufils E, Bourbao-Tournois C, Laribi S, et al. Follow-up of adults with noncritical COVID-19 two months after symptom onset. Clin Microbiol Infect. febrero de 2021;27(2):258-63.
dc.source.bibliographicCitationArnold DT, Hamilton FW, Milne A, Morley AJ, Viner J, Attwood M, et al. Patient outcomes after hospitalisation with COVID-19 and implications for follow-up: results from a prospective UK cohort. Thorax. abril de 2021;76(4):399-401.
dc.source.bibliographicCitationMoreno-Pérez O, Merino E, Leon-Ramirez JM, Andres M, Ramos JM, Arenas-Jiménez J, et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. marzo de 2021;82(3):378-83.
dc.source.bibliographicCitationHuang C, Huang L, Wang Y, Li X, Ren L, Gu X, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. The Lancet. enero de 2021;397(10270):220-32.
dc.source.bibliographicCitationNalbandian A, Sehgal K, Gupta A, Madhavan MV, McGroder C, Stevens JS, et al. Post-acute COVID-19 syndrome. Nat Med. abril de 2021;27(4):601-15.
dc.source.bibliographicCitationBrodin P, Casari G, Townsend L, O’Farrelly C, Tancevski I, Löffler-Ragg J, et al. Studying severe long COVID to understand post-infectious disorders beyond COVID-19. Nat Med. mayo de 2022;28(5):879-82
dc.source.bibliographicCitationCrook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and management. BMJ. 26 de julio de 2021;n1648.
dc.source.bibliographicCitationSudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. abril de 2021;27(4):626-31
dc.source.bibliographicCitationLopez-Leon S, Wegman-Ostrosky T, Perelman C, Sepulveda R, Rebolledo PA, Cuapio A, et al. More than 50 Long-term effects of COVID-19: a systematic review and meta-analysis [Internet]. Infectious Diseases (except HIV/AIDS); 2021 ene [citado 20 de diciembre de 2022]. Disponible en: http://medrxiv.org/lookup/doi/10.1101/2021.01.27.21250617
dc.source.bibliographicCitationImam Z, Odish F, Gill I, O’Connor D, Armstrong J, Vanood A, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID‐19 patients in Michigan, United States. J Intern Med. octubre de 2020;288(4):469-76.
dc.source.bibliographicCitationYanez ND, Weiss NS, Romand JA, Treggiari MM. COVID-19 mortality risk for older men and women. BMC Public Health. diciembre de 2020;20(1):1742.
dc.source.bibliographicCitationYang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. mayo de 2020;94:91-5.
dc.source.bibliographicCitationFadini GP, Morieri ML, Longato E, Avogaro A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. J Endocrinol Invest. junio de 2020;43(6):867-9
dc.source.bibliographicCitationKhan MMA, Khan MN, Mustagir MG, Rana J, Islam MS, Kabir MI. Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis. J Glob Health. diciembre de 2020;10(2):020503.
dc.source.bibliographicCitationZhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. octubre de 2020;99:47-56
dc.source.bibliographicCitationFond G, Nemani K, Etchecopar-Etchart D, Loundou A, Goff DC, Lee SW, et al. Association Between Mental Health Disorders and Mortality Among Patients With COVID-19 in 7 Countries: A Systematic Review and Meta-analysis. JAMA Psychiatry. 1 de noviembre de 2021;78(11):1208.
dc.source.bibliographicCitationLiu N, Sun J, Wang X, Zhao M, Huang Q, Li H. The Impact of Dementia on the Clinical Outcome of COVID-19: A Systematic Review and Meta-Analysis. J Alzheimers Dis. 8 de diciembre de 2020;78(4):1775-82.
dc.source.bibliographicCitationYang J, Hu J, Zhu C. Obesity aggravates COVID‐19: A systematic review and meta‐analysis. J Med Virol. enero de 2021;93(1):257-61.
dc.source.bibliographicCitationPatanavanich R, Glantz SA. Smoking Is Associated With COVID-19 Progression: A Meta-analysis. Nicotine Tob Res. 24 de agosto de 2020;22(9):1653-6.
dc.source.bibliographicCitationWestern Cape Department of Health in collaboration with the National Institute for Communicable Diseases, South Africa. Erratum to: Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa. Clin Infect Dis. 9 de abril de 2022;74(7):1321-1321.
dc.source.bibliographicCitationBhaskaran K, Rentsch CT, MacKenna B, Schultze A, Mehrkar A, Bates CJ, et al. HIV infection and COVID-19 death: a population-based cohort analysis of UK primary care data and linked national death registrations within the OpenSAFELY platform. Lancet HIV. enero de 2021;8(1):e24-32.
dc.source.bibliographicCitationSsentongo P, Ssentongo AE, Heilbrunn ES, Ba DM, Chinchilli VM. Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis. Hirst JA, editor. PLOS ONE. 26 de agosto de 2020;15(8):e0238215.
dc.source.bibliographicCitationBrenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry. Gastroenterology. agosto de 2020;159(2):481-491.e3.
dc.source.bibliographicCitationMichelena X, Borrell H, López-Corbeto M, López-Lasanta M, Moreno E, Pascual-Pastor M, et al. Incidence of COVID-19 in a cohort of adult and paediatric patients with rheumatic diseases treated with targeted biologic and synthetic disease-modifying anti-rheumatic drugs. Semin Arthritis Rheum. agosto de 2020;50(4):564-70.
dc.source.bibliographicCitationCMMID COVID-19 Working Group, Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, et al. Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 13 de mayo de 2021;593(7858):270-4.
dc.source.bibliographicCitationhe COVID-19 Genomics UK (COG-UK) consortium, Volz E, Mishra S, Chand M, Barrett JC, Johnson R, et al. Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England. Nature. 13 de mayo de 2021;593(7858):266-9.
dc.source.bibliographicCitationUriu K, Kimura I, Shirakawa K, Takaori-Kondo A, Nakada T aki, Kaneda A, et al. Neutralization of the SARS-CoV-2 Mu Variant by Convalescent and Vaccine Serum. N Engl J Med. 16 de diciembre de 2021;385(25):2397-9
dc.source.bibliographicCitationAlvarez-Moreno C, Valderrama-Beltran SL, Silva R, De La Hoz Siegler IH, Varón Vega FA, Martínez-Vernaza S, et al. Associated factors for mortality in a COVID-19 colombian cohort: is the third wave relevant when Mu variant was predominant epidemiologically? Travel Med Infect Dis. mayo de 2023;53:102579
dc.source.bibliographicCitationKarlsen TH. Understanding COVID-19 through genome-wide association studies. Nat Genet. abril de 2022;54(4):368-9.
dc.source.bibliographicCitationde Araújo JLF, Menezes D, Aguiar RS de, Souza RP de. IFITM3, FURIN, ACE1, and TNF-α Genetic Association With COVID-19 Outcomes: Systematic Review and Meta-Analysis. Front Genet. 1 de abril de 2022;13:775246.
dc.source.bibliographicCitationDownes DJ, Cross AR, Hua P, Roberts N, Schwessinger R, Cutler AJ, et al. Identification of LZTFL1 as a candidate effector gene at a COVID-19 risk locus. Nat Genet. noviembre de 2021;53(11):1606-15.
dc.source.bibliographicCitationEspinas NA, Tu LN, Furci L, Shimajiri Y, Harukawa Y, Miura S, et al. Transcriptional regulation of genes bearing intronic heterochromatin in the rice genome. Mittelsten Scheid O, editor. PLOS Genet. 18 de marzo de 2020;16(3):e1008637.
dc.source.bibliographicCitationRose AB. Introns as Gene Regulators: A Brick on the Accelerator. Front Genet. 7 de febrero de 2019;9:672.
dc.source.bibliographicCitationLópez-Rodríguez R, Del Pozo-Valero M, Corton M, Minguez P, Ruiz-Hornillos J, Pérez-Tomás ME, et al. Presence of rare potential pathogenic variants in subjects under 65 years old with very severe or fatal COVID-19. Sci Rep. 20 de junio de 2022;12(1):10369.
dc.source.bibliographicCitationKosmicki JA, Horowitz JE, Banerjee N, Lanche R, Marcketta A, Maxwell E, et al. A catalog of associations between rare coding variants and COVID-19 outcomes [Internet]. Infectious Diseases (except HIV/AIDS); 2020 nov [citado 20 de diciembre de 2022]. Disponible en: http://medrxiv.org/lookup/doi/10.1101/2020.10.28.20221804
dc.source.bibliographicCitationButler-Laporte G, Povysil G, Kosmicki JA, Cirulli ET, Drivas T, Furini S, et al. Exome-wide association study to identify rare variants influencing COVID-19 outcomes: Results from the Host Genetics Initiative [Internet]. Infectious Diseases (except HIV/AIDS); 2022 mar [citado 20 de diciembre de 2022]. Disponible en: http://medrxiv.org/lookup/doi/10.1101/2022.03.28.22273040
dc.source.bibliographicCitationBats ML, Rucheton B, Fleur T, Orieux A, Chemin C, Rubin S, et al. Covichem: A biochemical severity risk score of COVID-19 upon hospital admission. Lazzeri C, editor. PLOS ONE. 6 de mayo de 2021;16(5):e0250956.
dc.source.bibliographicCitationHaimovich AD, Ravindra NG, Stoytchev S, Young HP, Wilson FP, van Dijk D, et al. Development and Validation of the Quick COVID-19 Severity Index: A Prognostic Tool for Early Clinical Decompensation. Ann Emerg Med. octubre de 2020;76(4):442-53
dc.source.bibliographicCitationDite GS, Murphy NM, Spaeth E, Allman R, Lifelines Corona Research Initiative. Validation of a clinical and genetic model for predicting severe COVID-19. Epidemiol Infect. 2022;150:e91.
dc.source.bibliographicCitationMGI sequencing platforms: High-throughput gene sequencers, DNBSEQTM sequencing technology-MGI-Leading Life Science Innovation [Internet]. [citado 29 de diciembre de 2022]. Disponible en: https://en.mgi-tech.com/products/
dc.source.bibliographicCitationLi H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics. 15 de agosto de 2009;25(16):2078-9.
dc.source.bibliographicCitationIoannidis NM, Rothstein JH, Pejaver V, Middha S, McDonnell SK, Baheti S, et al. REVEL: An Ensemble Method for Predicting the Pathogenicity of Rare Missense Variants. Am J Hum Genet. octubre de 2016;99(4):877-85.
dc.source.bibliographicCitationCDC. Centers for Disease Control and Prevention. 2020 [citado 20 de diciembre de 2022]. Coronavirus Disease 2019 (COVID-19). Disponible en: https://www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html
dc.source.bibliographicCitationZheng Z, Peng F, Xu B, Zhao J, Liu H, Peng J, et al. Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis. J Infect. agosto de 2020;81(2):e16-25.
dc.source.bibliographicCitationLim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. enero de 2021;17(1):11-30.
dc.source.bibliographicCitationLiu D, Zhang T, Wang Y, Xia L. The Centrality of Obesity in the Course of Severe COVID-19. Front Endocrinol. 11 de marzo de 2021;12:620566.
dc.source.bibliographicCitationHe X, Cheng X, Feng X, Wan H, Chen S, Xiong M. Clinical Symptom Differences Between Mild and Severe COVID-19 Patients in China: A Meta-Analysis. Front Public Health. 14 de enero de 2021;8:561264.
dc.source.bibliographicCitationParasher A. COVID-19: Current understanding of its Pathophysiology, Clinical presentation and Treatment. Postgrad Med J. mayo de 2021;97(1147):312-20.
dc.source.bibliographicCitationFoster KJ, Jauregui E, Tajudeen B, Bishehsari F, Mahdavinia M. Smell loss is a prognostic factor for lower severity of coronavirus disease 2019. Ann Allergy Asthma Immunol. octubre de 2020;125(4):481-3.
dc.source.bibliographicCitationPeghin M, Palese A, Venturini M, De Martino M, Gerussi V, Graziano E, et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. octubre de 2021;27(10):1507-13.
dc.source.bibliographicCitationAsadi-Pooya AA, Akbari A, Emami A, Lotfi M, Rostamihosseinkhani M, Nemati H, et al. Risk Factors Associated with Long COVID Syndrome: A Retrospective Study. Iran J Med Sci [Internet]. noviembre de 2021 [citado 20 de diciembre de 2022];46(6). Disponible en: https://doi.org/10.30476/ijms.2021.92080.2326
dc.source.bibliographicCitationde Oliveira JF, de Ávila RE, de Oliveira NR, da Cunha Severino Sampaio N, Botelho M, Gonçalves FA, et al. Persistent symptoms, quality of life, and risk factors in long COVID: a cross-sectional study of hospitalized patients in Brazil. Int J Infect Dis. septiembre de 2022;122:1044-51.
dc.source.bibliographicCitationBordon Y. A new set of genes linked to critical COVID-19. Nat Rev Immunol. abril de 2022;22(4):208-208.
dc.source.bibliographicCitationZheng J, Zhang Y, Zhao H, Liu Y, Baird D, Karim MA, et al. Multi-ancestry Mendelian randomization of omics traits revealing drug targets of COVID-19 severity. eBioMedicine. julio de 2022;81:104112.
dc.source.bibliographicCitationRao S, Baranova A, Cao H, Chen J, Zhang X, Zhang F. Genetic mechanisms of COVID-19 and its association with smoking and alcohol consumption. Brief Bioinform. 5 de noviembre de 2021;22(6):bbab284.
dc.source.bibliographicCitationZhang HL, Wu J, Zhu J. The Immune-Modulatory Role of Apolipoprotein E with Emphasis on Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis. Clin Dev Immunol. 2010;2010:1-10.
dc.source.bibliographicCitationOstendorf BN, Patel MA, Bilanovic J, Hoffmann HH, Carrasco SE, Rice CM, et al. Common human genetic variants of APOE impact murine COVID-19 mortality. Nature. 10 de noviembre de 2022;611(7935):346-51.
dc.source.bibliographicCitationvan der Made CI, Netea MG, van der Veerdonk FL, Hoischen A. Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19. Genome Med. 19 de agosto de 2022;14(1):96.
dc.source.bibliographicCitationvan der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, et al. Presence of Genetic Variants Among Young Men With Severe COVID-19. JAMA. 18 de agosto de 2020;324(7):663
dc.source.bibliographicCitationtikker BS, Stik G, van Ouwerkerk AF, Trap L, Spicuglia S, Hendriks RW, et al. Severe COVID-19-associated variants linked to chemokine receptor gene control in monocytes and macrophages. Genome Biol. diciembre de 2022;23(1):96
dc.source.bibliographicCitationKhalil BA, Noha Mousaad Elemam, Maghazachi AA. Chemokines and chemokine receptors during COVID-19 infection. Comput Struct Biotechnol J. 2021;19:976-88.
dc.source.bibliographicCitationVoloudakis G, Vicari JM, Venkatesh S, Hoffman GE, Dobrindt K, Zhang W, et al. A translational genomics approach identifies IL10RB as the top candidate gene target for COVID-19 susceptibility. Npj Genomic Med. 5 de septiembre de 2022;7(1):52
dc.source.bibliographicCitationFricke-Galindo I, Falfán-Valencia R. Genetics Insight for COVID-19 Susceptibility and Severity: A Review. Front Immunol. 1 de abril de 2021;12:622176.
dc.source.bibliographicCitationChen Y, Zhou X, Yan H, Huang H, Li S, Jiang Z, et al. CANPT Score: A Tool to Predict Severe COVID-19 on Admission. Front Med. 18 de febrero de 2021;8:608107.
dc.source.bibliographicCitationWoolhouse M. How to make predictions about future infectious disease risks. Philos Trans R Soc B Biol Sci. 12 de julio de 2011;366(1573):2045-54.
dc.source.bibliographicCitationMergenthaler C, Gurp M, Rood E, Bakker M. The study of spatial autocorrelation for infectious disease epidemiology decision-making: a systematized literature review. CABI Rev. 15 de julio de 2022;2022:cabireviews202217018
dc.source.instnameinstname:Universidad del Rosario
dc.source.reponamereponame:Repositorio Institucional EdocUR
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjectMedicina de precisión
dc.subjectFactores genéticos
dc.subjectFactores clínicos
dc.subjectModelo predictivo
dc.subjectSeveridad COVID-19
dc.subjectCOVID-19 prolongado
dc.subject.keywordGenetics
dc.subject.keywordCOVID-19
dc.subject.keywordSARS-CoV-2
dc.subject.keywordPrecision medicine
dc.subject.keywordGenetic Factors
dc.subject.keywordClinical factors
dc.subject.keywordPredictive model
dc.subject.keywordCOVID-19 severity
dc.subject.keywordProlonged COVID-19
dc.titleFactores Genéticos y no genéticos asociados a la severidad clínica de la infección por SARS-CoV-2 y COVID-19 prolongado en una muestra de la población colombiana
dc.title.TranslatedTitleGenetic and non-genetic factors associated with severe SARS-COV-2 Infection and long-COVID in a sample of tha colombian population
dc.typemasterThesis
dc.type.documentTesis
dc.type.hasVersioninfo:eu-repo/semantics/acceptedVersion
dc.type.spaTesis
local.department.reportEscuela de Medicina y Ciencias de la Salud
Archivos
Bloque original
Mostrando1 - 1 de 1
Miniatura
Nombre:
Factores_geneticos_y_no_geneticos_asociados_a_la_severidad_clinica_de_la_infeccion_por_SARS_CoV-2_y_COVID-19_prolongado_en_una-muestra_de_la_poblacion_colombiana.pdf
Tamaño:
16.39 MB
Formato:
Adobe Portable Document Format
Descripción:
Descargar
Colecciones
Maestría en Epidemiología